2nd November 2005

COBALZ today announced the grant of a European patent for the use of its novel B vitamin formulations in the treatment and prevention of dementia, including Alzheimer's disease

The European patent is EP 1381373: ‘Medical Compositions for use in the treatment or prevention of a functional vitamin B12 deficiency’

Neil McCaddon, Head of Licensing & Corporate Development for COBALZ, said: ‘This is a significant stage in the development of COBALZ’s platform technology.  We look forward to developing our other patent-protected compounds for use in the treatment and prevention of this devastating disease’

Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated six million people in Europe alone.  COBALZ is actively seeking licensing and development partners for Europe and the rest of the global market